It also demonstrates the potency of dexamethasone in suppressing ACTH and promoting regression of TARTs, along with its potential risks, including iatrogenic Cushing’s syndrome, cardiovascular morbidity, and reduced bone mineral density (BMD). Here, POMC is linked to Cushing syndrome due to macronodular adrenal hyperplasia.